公开(公告)号：USRE45847E1

公开(公告)日：2016-01-19

申请号：US14219900

申请日：2014-03-19

申请人： Amgen Fremont Inc. ,  Pfizer Inc.

发明人： Nicholas Pullen ,  Elizabeth Molloy ,  Sirid-Aimee Kellermann ,  Larry L. Green ,  Mary Haak-Frendscho

IPC分类号： C12N5/00 ,  C07K16/28 ,  A61K39/00 ,  C07K14/705

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K14/70503 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56972 ,  G01N33/6854 ,  G01N2333/70503 ,  G01N2333/70546

摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.

摘要翻译： 本发明涉及特异性结合MAdCAM，优选人MAdCAM的人抗体及其抗原结合部分的抗体，其功能是抑制MAdCAM。 本发明还涉及人抗MAdCAM抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗MAdCAM抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗MAdCAM抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗MAdCAM抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。

公开(公告)号：US20170051057A1

公开(公告)日：2017-02-23

申请号：US15086930

申请日：2016-03-31

申请人： Pfizer Inc. ,  Amgen Fremont Inc.

发明人： Nicholas Pullen ,  Elizabeth Molloy ,  Sirid-Aimee Kellermann ,  Larry L. Green ,  Mary Haak-Frendscho

IPC分类号： C07K16/28 ,  G01N33/569 ,  G01N33/68

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K14/70503 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56972 ,  G01N33/6854 ,  G01N2333/70503 ,  G01N2333/70546

摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.

摘要翻译： 本发明涉及特异性结合MAdCAM，优选人MAdCAM的人抗体及其抗原结合部分的抗体，其功能是抑制MAdCAM。 本发明还涉及人抗MAdCAM抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗MAdCAM抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗MAdCAM抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗MAdCAM抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。

公开(公告)号：US20190300605A1

公开(公告)日：2019-10-03

申请号：US16282157

申请日：2019-02-21

申请人： Pfizer Inc. ,  Amgen Fremont Inc.

发明人： Nicholas Pullen ,  Elizabeth Molloy ,  Sirid-Aimee Kellermann ,  Larry L. Green ,  Mary Haak-Frendscho

IPC分类号： C07K16/28 ,  G01N33/569 ,  G01N33/68

摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.

公开(公告)号：US10259872B2

公开(公告)日：2019-04-16

申请号：US15086930

申请日：2016-03-31

申请人： Pfizer Inc. ,  Amgen Fremont Inc.

发明人： Nicholas Pullen ,  Elizabeth Molloy ,  Sirid-Aimee Kellermann ,  Larry L. Green ,  Mary Haak-Frendscho

IPC分类号： C12P21/00 ,  C12N5/20 ,  C07K16/28 ,  G01N33/569 ,  G01N33/68 ,  A61K39/00 ,  C07K14/705

摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.